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ABSTRACT
Objective To investigate the association between 
physician characteristics and the value of industry 
payments.
Design Observational study.
Setting and participants Using the 2015–2017 Open 
Payments reports of industry payments linked to the 
Physician Compare database, we examined the association 
between physician characteristics (physician sex, years 
in practice, medical school attended and specialty) and 
the industry payment value, adjusting for other physician 
characteristic and institution fixed effects (effectively 
comparing physicians practicing at the same institution).
Main outcome measures Our primary outcome was the 
value of total industry payments to physicians including 
(1) general payments (all forms of payments other than 
those classified for research purpose, eg, consulting fees, 
food, beverage), (2) research payments (payments for 
research endeavours under a written contract or protocol) 
and (3) ownership interests (eg, stock or stock options, 
bonds). We also investigated each category of payment 
separately.
Results Of 544 264 physicians treating Medicare 
beneficiaries, a total of $5.8 billion in industry payments 
were made to 365 801 physicians during 2015–2017. 
The top 5% of physicians, by cumulative payments, 
accounted for 91% of industry payments. Within the 
same institution, male physicians, physicians with 21–30 
years in practice and physicians who attended top 50 US 
medical schools (based on the research ranking) received 
higher industry payments. Across specialties, orthopaedic 
surgeons, neurosurgeons and endocrinologists received 
the highest payments. When we investigated individual 
types of payment, we found that orthopaedic surgeons 
received the highest general payments; haematologists/
oncologists were the most likely to receive research 
payments and surgeons were the most likely to receive 
ownership interests compared with other types of 
physicians.
Conclusions Industry payments to physicians were highly 
concentrated among a small number of physicians. Male 
sex, longer length of time in clinical practice, graduated 
from a top-ranked US medical school and practicing 
certain specialties, were independently associated with 
higher industry payments.
InTRODuCTIOn
A significant body of research suggests that 
physicians’ financial relationships with 
industry may influence medical research, 
education and patient care, including clin-
ical decisions about which medicines to 
prescribe.1–11 Concerns about the conse-
quences of physicians’ financial conflict of 
interest and inconsistent disclosure of these 
conflicts, led to the creation of the Open 
Payments programme under the Physician 
Payment Sunshine Act (known as the ‘Sunshine 
Act’, enacted as part of the Affordable Care 
Act). The Sunshine Act requires medical 
product manufacturers and group purchasing 
organisations (GPOs) to publicly report data 
on all payments and ownership interests made 
to licensed physicians (except residents) and 
teaching hospitals since 2013.12 The Open 
Payments database is the most exhaustive and 
reliable source of data on industry payments 
to physicians to date.13–15
The characteristics of physicians who 
receive large payments from industry remain 
incompletely characterised. Several studies 
have reported that industry payments may 
Strength and limitations of this study
 ► The latest and most comprehensive data of the finan-
cial relationships between industry and physicians 
were used by linking a nationally representative 
Open Payments database with the national database 
of physicians treating Medicare beneficiaries.
 ► We examined both the total amount of industry pay-
ments to physicians and each category of payment 
(ie, general payments, research payments and own-
ership interests), which have not been investigated 
in prior studies.
 ► Limitations are the physician database was restrict-
ed to physicians treating Medicare beneficiaries and 
the temporal relationship could not be assessed 
with the cross-sectional design.
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vary substantially based on physicians’ sex,14–17 clin-
ical experience16 18 and specialty.10 15 19 20 In addition, a 
recent study that reported association of physicians’ alma 
mater, medical school ranking and their prescription 
patterns (for opioids), sheds light on the importance of 
medical education on physician behaviour, which could 
potentially impact how industry approach physicians.21 
However, these studies did not adjust for a comprehen-
sive set of physician characteristics, due to lack of the 
data, and, therefore, it is possible that their findings may 
be biased if they left out an important physician-level 
confounder. In other words, it remains unclear whether 
four important characteristics of physicians—physicians’ 
sex, years in practice, finely categorised specialties and 
medical school attended—are independently associated 
with the value of industry payments they receive. More-
over, most prior work on this topic has focused exclusively 
on non-research payments, despite the fact that some 
pharmaceutical companies have been using research 
payments aggressively to influence physicians’ prescrip-
tion of opioid products,22–24 underscoring the impor-
tance of evaluating all forms of payments. Therefore, a 
better characterisation of physician-level factors associ-
ated with higher industry payments—both non-research 
and research payments from industry—would help to 
advance our understanding of the financial relationships 
between industry and practicing US physicians and their 
potential impact on prescribing patterns and care quality.
In this study, we used a nationally representative data-
base of industry payments to physicians linked with a 
comprehensive database of physicians treating Medicare 
beneficiaries, to investigate associations between a broad 
set of physician characteristics including—sex, years in 
practice, medical school and clinical specialty—and the 
value of payments (total amount of industry payments, as 
well as non-research and research payments separately) 
received from industry.
MeThODS
Data sources
We linked three databases: (1) the 2015–2017 Centers for 
Medicare and Medicaid Services (CMS) Open Payments 
database (accessed September 2018), (2) the CMS 
National Plan & Provider Enumeration System (NPPES) 
database (accessed September 2018) and (3) the CMS 
Physician Compare database (accessed January 2019).25 
Data from the 2015–2017 Open Payments programme 
included data on all general payments, research payments 
and ownership interests that industry paid physicians in 
each year. Biomedical companies report payment infor-
mation to the CMS and physicians are asked to review the 
information before publication and dispute submitted 
reports if the information is incorrect. The CMS reported 
more than 98.8% of submitted payment records were 
validated in 2014 using the automated algorithm, which 
rejects payment records if they report inconsistent 
physician identifiers and provides real-time feedback to 
industries.13 The Physician Compare database developed 
by the CMS contains general information on all eligible 
healthcare providers (physicians, nurses and so on, with 
at least one practice location address/specialty code in 
the Medicare Provider Enrollment, Chain, and Owner-
ship System who submitted at least one annual Medicare 
claim) including the National Provider Identification 
(NPI) number registry, sex, years in practice, specialty, 
medical school attended and practice location.25
We first linked physician information from the Open 
Payments database with the 2017 NPPES database using 
physicians’ full name and the zip code for their primary 
practice location, an approach employed in previous 
studies.10 15 19 Next, we used each physician’s NPI number 
to linked the new merged dataset containing Open 
Payments and NPPES data with the Physician Compare 
database. Given that physicians who do not treat Medi-
care beneficiaries were not included in the Physician 
Compare database, our final sample size became 544 264 
(see online supplementary figure 1 for more details).
Physician characteristics
We examined four characteristics of physicians: sex, years 
in practice, medical school attended and specialty. We 
defined years in practice as years since graduation from 
medical school and categorised physicians into four 
groups: ≤10, 11–20, 21–30 and >30 years since gradua-
tion. As in prior studies, we used the 2017 U.S. News & 
World Report research ranking,26 27 to categorise medical 
schools into three groups: (1) top 20 US medical schools 
for research, (2) US medical schools ranked between 21 
and 50 and (3) other medical schools (since only top 50 
medical schools are ranked, we classified all unranked 
and foreign medical schools into this ‘other’ category). 
In table 1, we classified physician specialty into 33 distinct 
categories. We created indicator variables for practice 
location using the physical address of individual physi-
cians in the NPPES database.
Payment data
Physician payments were classified into three catego-
ries: general payments, research payments and owner-
ship interests. General payments included all forms 
of payments other than those classified for research 
purposes, including food and beverage, travel and 
lodging, speaker compensation, honoraria, consulting 
fees, gifts and education materials (eg, textbooks and 
reprints of journal articles). Research payments are finan-
cial payments related to research under a written contract 
or protocol (including payments for medical research 
writing or publication). Ownership interests include 
stocks or stock options (not publicly traded), partnership 
shares, bonds and ownership stake in a limited liability 
company.
Our primary outcome was the total annual value of 
reported payments—the sum of general payments, 
research payments and ownership interests—to physicians 
(calculated by dividing the total value of payments from 
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Table 1 Physician characteristics and type of industry payments
Total physicians in the 
final database
Physicians who received 
general payments
Physicians who received 
research payments
Physicians who received 
ownership interests
Number of physicians 544 264 365 441 9456 2648
Sex, N (%)
  Female 173 715 (31.9) 106 308 (29.1) 1866 (19.7) 326 (12.3)
  Male 370 549 (68.1) 259 133 (70.9) 7590 (80.3) 2322 (87.7)
Years in practice, mean (SD) 23 (12) 23 (12) 26 (10) 29 (10)
Medical school attended*, N (%)
  Top 20 schools in USA 60 711 (11.2) 39 250 (10.7) 1793 (19.0) 436 (16.5)
  US schools ranked 21–50 95 294 (17.5) 62 349 (17.1) 1838 (19.4) 627 (23.7)
  Other schools 388 259 (71.3) 263 842 (72.2) 5825 (61.6) 1585 (59.9)
Specialty, N (%)
  Primary care
  Internal Medicine 102 193 (18.8) 65 123 (17.8) 1217 (12.9) 152 (5.7)
  Family Medicine 81 305 (14.9) 53 913 (14.8) 439 (4.6) 218 (8.2)
  Paediatrics 6474 (1.2) 3613 (1.0) 91 (1.0) 8 (0.3)
  Hospitalist 6888 (1.3) 3481 (1.0) 17 (0.2) 0 (0.0)
  Surgery
  Orthopaedic 21 444 (3.9) 17 757 (4.9) 465 (4.9) 571 (21.6)
  Neurosurgery 4568 (0.8) 3688 (1.0) 209 (2.2) 118 (4.5)
  Thoracic/Vascular 2755 (0.5) 2296 (0.6) 100 (1.1) 14 (0.5)
  Urology 8077 (1.5) 6794 (1.9) 192 (2.0) 663 (25.0)
  Colorectal 945 (0.2) 760 (0.2) 33 (0.4) 3 (0.1)
  General 25 543 (4.7) 19 446 (5.3) 467 (4.9) 64 (2.4)
  Plastic 2634 (0.5) 2079 (0.6) 46 (0.5) 7 (0.3)
  Otolaryngology 8148 (1.5) 6312 (1.7) 150 (1.6) 51 (1.9)
  Obstetrics/Gynaecology 28 905 (5.3) 21 796 (6.0) 505 (5.3) 53 (2.0)
  Specialists
  Endocrinology 4444 (0.8) 3406 (0.9) 216 (2.3) 7 (0.3)
  Rheumatology 3555 (0.7) 2767 (0.8) 244 (2.6) 36 (1.4)
  Haematology/Oncology 9369 (1.7) 7513 (2.1) 1040 (11.0) 185 (7.0)
  Neurology 11 447 (2.1) 8365 (2.3) 564 (6.0) 14 (0.5)
  Dermatology 10 303 (1.9) 7628 (2.1) 360 (3.8) 21 (0.8)
  Cardiology 18 847 (3.5) 15 457 (4.2) 567 (6.0) 87 (3.3)
  Allergy/Immunology 2887 (0.5) 2267 (0.6) 155 (1.6) 13 (0.5)
  Ophthalmology 15 850 (2.9) 12 458 (3.4) 476 (5.0) 61 (2.3)
  Gastroenterology 10 436 (1.9) 8479 (2.3) 361 (3.8) 21 (0.8)
  Infectious Diseases 4654 (0.9) 3036 (0.8) 94 (1.0) 1 (0.0)
  Pulmonology 5514 (1.0) 4192 (1.2) 122 (1.3) 3 (0.1)
  Paediatric Specialty 3566 (0.7) 2172 (0.6) 138 (1.5) 2 (0.1)
  Psychiatry 21 642 (4.0) 11 900 (3.3) 240 (2.5) 12 (0.5)
  Radiology 24 816 (4.6) 12 094 (3.3) 241 (2.6) 79 (3.0)
  Nephrology 6958 (1.3) 5406 (1.5) 141 (1.5) 9 (0.3)
  Rehabilitation 7621 (1.4) 4558 (1.3) 34 (0.4) 13 (0.5)
  Emergency Medicine 18 612 (3.4) 9619 (2.6) 122 (1.3) 14 (0.5)
  Anaesthesiology 35 986 (6.6) 21 827 (6.0) 124 (1.3) 69 (2.6)
  Others† 27 878 (5.1) 15 239 (4.2) 286 (3.0) 79 (3.0)
*Defined based on the U.S. News & World Report ranking (research ranking) in 2017.
†Others include surgical oncology, oral surgery, radio oncology, pathology, nuclear medicine and so on.
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industry in 2015–2017 by three). Secondary outcomes 
were the annual value of each type of payment (ie, general 
payments, research payments and ownership interests) 
in 2015–2017. We focused on the total value of industry 
payments (we also examined the number of industry 
payments in a sensitivity analysis), because payments 
may be paid at once or split into multiple payments. We 
assumed that physicians who lacked payment informa-
tion in the Open Payments database had not received 
payments from industry.
Statistical analyses
First, we analysed the concentration of total industry 
payments across physicians. We also ranked physicians 
by total value of payments received from industry and 
determined the proportion of total industry payments 
that were concentrated among physicians in the top 1% 
and 5% of all physicians by size of total industry payments 
from 2015 to 2017.
Second, we examined the association between physi-
cian characteristics and annual total industry payment 
value by constructing multivariable negative binomial 
regression models (to account for a right-skewed distri-
bution of industry payments), adjusting for other physi-
cian characteristics and institution fixed effects. Physician 
characteristics evaluated in this model included sex, 
years in practice, medical school attended and clinical 
specialty. Institution fixed effects—indicator variables 
for each institution identified using each physician’s 
primary practice address—were included to account for 
both measured and unmeasured characteristics of institu-
tions that do not vary over time, effectively allowing us to 
compare physicians practicing in the same institution.28–30 
The unit of analysis was physicians and SEs were clustered 
at the institution level to account for potential correla-
tions between physicians practicing in the same institu-
tion.31 To calculate adjusted industry payment values for 
each group of physicians, after fitting regression models, 
we estimated predicted payment value for each physician, 
fixing physician characteristics at each level of the cate-
gories and averaged over our national sample (known as 
the marginal standardisation form of predictive margins, 
predictive margins, or margins of responses).32
Finally, we used a similar approach to that employed in 
our analysis of total industry payments to estimate associa-
tions between individual physician characteristics and the 
magnitude of each payment type separately (ie, general 
payments, research payments and ownership interests). 
For the analysis of general payments, as the industry 
marketing to physicians for drugs may have a different 
pattern than that for devices, we also conducted the 
analysis restricting to the payments made for drugs. For 
the analyses of research payments and ownership inter-
ests, given that the majority of physicians were receiving 
zero payment (98.3% and 99.5% of physicians were not 
receiving any research payments and ownership inter-
ests, respectively), we used two-part regression models33 
and evaluated physician characteristics associated with 
the odds of receiving any payments, as well as adjusted 
payment values for physicians who were receiving any 
payments (the first part was a logistic regression model 
estimating non-zero payments and the second part was a 
negative binomial regression model estimating the value 
of payments). For the analysis of ownership interests, 
we categorised physicians into four different specialties 
(primary care, surgery, specialists and others) to avoid 
unstable estimates due to smaller sample size.
Sensitivity analyses
We conducted sensitivity analyses for the analysis of total 
industry payments. First, to evaluate if our definitions of 
industry payments impacted our findings, we conducted 
multivariable logistic regression analyses using alternative 
definitions of industry payments: (1) whether physicians 
received any industry payments and (2) whether physi-
cians received industry payments greater than $5000 
(because the US Department of Health and Human 
Services specifically identifies payments exceeding this 
threshold as significant financial interests that require 
disclosure). Second, to test the impact of how we specify 
the distribution of payment data, we used alternative 
model specifications: (1) a two-part model33 (the first 
part was a logistic regression model, estimating non-zero 
payments and the second part was a negative binomial 
regression model, estimating the value of payments) and 
(2) ordinary least square regression with Huber-White 
heteroscedasticity-robust SEs. Last, to evaluate the gener-
alisability of our primary analysis to physicians who do not 
treat Medicare beneficiaries (and therefore, not included 
in the Physician Compare database), we examined the 
association between physician characteristics included in 
the Open Payments-NPPES linked database (physician 
sex and specialty) and the value of industry payments, 
without restricting physicians included in the Physician 
Compare database. All analyses were conducted using 
Stata, V.15 (Stata).
Patient and public involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for design or implementation of the 
study. No patients were asked to advise on interpretation 
or writing up of results. There are no plans to dissemi-
nate the results of the research to study participants or 
the relevant patient community.
ReSulTS
Of 544 264 physicians who were treating Medicare bene-
ficiaries, a total of $5.8 billion in industry payments were 
made to 365 801 physicians in 2015–2017, with a median 
(IQR) annual payment value of $199 ($42–$878). About 
68% (370 549/544 264) of physicians were male and 
mean (SD) years in practice was 23 (12) years (table 1). 
Industry payments were concentrated among a small 
number of physicians who accounted for a large share 
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of the total amount of payments (online supplementary 
figure 2). The top 1% and 5% of physicians accounted 
for 73% and 91% of total industry payments, respectively.
Association between physician characteristics and the value 
of total industry payments
After adjusting for other physician characteristics and 
institution fixed effects, male physicians received signifi-
cantly larger value of industry payments than female physi-
cians (adjusted annual payment value, $4164 for male vs 
$1650 for female; adjusted % difference, +152%; 95% CI 
+85% to +244%; p<0.001) meaning that the average 
male physicians had payments totalling 2.5 times that of 
female physicians (table 2). Physicians with 21–30 years in 
practice, received the largest payments, $5231 (adjusted 
annual payment value), followed by $3878, for >30 years, 
$3180, for 11–20 years and $906, for those with ≤10 years 
in practice. Physicians who attended US medical schools 
ranked below 50 or foreign medical schools, received 
lower payments compared with physicians who attended 
top 20 research medical schools.
After adjusting for other physician characteristics, 
orthopaedic surgeons received the highest payments 
(adjusted payment value, $18 650; 95% CI $14 475 to $22 
826), followed by neurosurgeons ($15 937; 95% CI $7861 
to $24 012) and endocrinologists ($11 829; 95% CI $9350 
to $14 309) (table 2). Hospitalists received the lowest 
payments ($312; 95% CI $212 to $412), followed by paedi-
atricians ($1050; 95% CI $742 to $1359) and anaesthesiol-
ogists ($1106; 95% CI $836 to $1375).
General payments
A total of 365 441 physicians treating Medicare benefi-
ciaries, received general payments in 2015–2017, with a 
median (IQR) annual payment value of $195 ($42–$852). 
Our results for general payments were similar to total 
payments (suggesting that our findings for total payments 
were driven largely by general payments). We found that 
general payments were higher for male physicians, physi-
cians with 21–30 years in practice and physicians who 
attended top 20 research medical schools (table 3A). 
Physicians in orthopaedic, neurosurgery and endocri-
nology received the highest payments, while hospitalists, 
emergency physicians and anaesthesiologists received the 
lowest general payments. When we restricted our anal-
ysis to payments for drugs and not for devices, we also 
observed the highest amount of industry payments were 
made to endocrinologists, but not to physicians in ortho-
paedic and neurosurgery (online supplementary table 1).
Research payments
A total of 9456 physicians treating Medicare benefi-
ciaries received research payments in 2015–2017, with 
a median (IQR) annual payment value of $827 ($233 
to $3667). We found that male physicians, physicians 
practicing for more than 10 years and physicians who 
attended top 20 medical schools, were associated with the 
receiving research payments (table 3B). Haematologists/
oncologists, allergists/immunologists, rheumatologists 
and endocrinologists were the most likely to receive 
research payments, while hospitalists, anaesthesiology and 
physicians in rehabilitation, were the least likely. Among 
physicians receiving any research payments, allergists/
immunologists received the largest research payments.
Ownership interests
A total of 2648 physicians treating Medicare beneficiaries 
received ownership interests in 2015–2017, with a median 
(IQR) annual value of $17 002 ($1324–$73 567). We found 
that male physicians, physicians practicing for more than 
10 years, and physicians who attended top 50 medical 
schools, were associated with the receiving ownership inter-
ests (table 3C). Across specialties, surgeons were receiving 
higher ownership interests than other types of physicians, 
including specialists and primary care physicians.
Sensitivity analyses
Our findings were not qualitatively affected using alter-
native definitions of industry payments (online supple-
mentary tables 2 and 3), and alternative specification of 
the distribution of payment data (online supplementary 
tables 4 and 5). Physicians and specialties were similar to 
physicians who were included in the Physician Compare 
database and those who were not (online supplementary 
tables 6) and our findings were similar when we analysed 
the data without restricting our study cohort to physicians 
included in the Physician Compare database (online 
supplementary tables 7).
DISCuSSIOn
Using payment data from industry to physicians in 
2015–2017 in the CMS Open Payments database linked 
with comprehensive data on practicing physicians in the 
U.S., we found that industry payments were concentrated 
among a small number of physicians; the top 5% of physi-
cians by total payment value accounted for 91% of total 
industry payments to physicians in 2015–2017. We also 
found that, within the same institution, male sex, physi-
cians who have more years in practice and those who grad-
uated from medical schools with highly-ranked research 
programmes, were associated with higher total value 
of industry payments. Across specialties, orthopaedic 
surgeons, neurosurgeons and endocrinologists received 
the highest total industry payments. Taken together, these 
findings extend our understanding of the financial rela-
tionships between industry and US practicing physicians 
and how industry payments to physicians may influence 
prescribing practices.
These findings have important policy implications. 
Although the total number of industry payments to physi-
cians has declined recently,18 34 the total dollar value of 
payments remains as high as $8.4 billion,34 indicating that 
improved transparency through the Physician Payments 
Sunshine Act alone may not be adequate to change how 
industry interact with physicians. Our findings suggest 
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Table 2 Comparison of industry total payment value according to physician characteristics
Mean value of payments
Adjusted % difference (95% CI) P valueUnadjusted Adjusted (95% CI)
Sex
  Female $1090 $1650 (1149 to 2151) Ref –
  Male $4735 $4164 (3304 to 5025) +152% (+85% to+244%) <0.001
Years in practice
  ≤10 $632 $906 (663 to 1148) Ref –
  11–20 $2712 $3180 (2420 to 3941) +251% (+135% to+424%) <0.001
  21–30 $5160 $5231 (3495 to 6966) +478% (+304% to+726%) <0.001
  >30 $4930 $3878 (3342 to 4414) +328% (+228% to+460%) <0.001
Medical school attended*
  Top 20 school in USA $5249 $3759 (3265 to 4254) Ref –
  US schools ranked 21–50 $5527 $5477 (2604 to 8350) +46% (-8% to +131%) 0.11
  Other schools $2830 $3003 (2687 to 3320) −20% (-31% to -7%) 0.004
Specialty
  Primary care
  Internal Medicine $1747 $2641 (1260 to 4022) Ref –
  Family Medicine $2590 $1515 (323 to 2706) −43% (−73% to +23%) 0.15
  Paediatrics $669 $1050 (742 to 1359) −60% (-78% to -27%) 0.003
  Hospitalist $208 $312 (212 to 412) −88% (-94% to -78%) <0.001
  Surgery
  Orthopaedic $23 897 $18 650 (14 475 to 22826) +606% (+327% to+1067%) <0.001
  Neurosurgery $20 156 $15 937 (7861 to 24012) +503% (+204% to+1098%) <0.001
  Thoracic/Vascular $5804 $4580 (3473 to 5686) +73% (+3% to+192%) 0.04
  Urology $4849 $4381 (3461 to 5300) +66% (-3% to +182%) 0.06
  Colorectal $3417 $3252 (2300 to 4204) +23% (-32% to +122%) 0.49
  General $2791 $2983 (2294 to 3672) +13% (-35% to +95%) 0.66
  Plastic $2650 $2467 (1894 to 3040) −7% (−47% to +64%) 0.81
  Otolaryngology $1400 $1333 (1062 to 1604) −50% (-70% to -14%) 0.01
  Obstetrics/Gynaecology $932 $1249 (921 to 1578) −53% (-74% to -15%) 0.01
  Specialists
  Endocrinology $11 327 $11 829 (9350 to 14309) +348% (+152% to+695%) <0.001
  Rheumatology $7252 $8049 (5982 to 10117) +205% (+73% to+436%) <0.001
  Haematology/Oncology $7578 $7676 (6288 to 9063) +191% (+68% to+402%) <0.001
  Neurology $6244 $7592 (5938 to 9247) +188% (+65% to+402%) <0.001
  Dermatology $4239 $5238 (4169 to 6307) +98% (+12% to+251%) 0.02
  Cardiology $6024 $4932 (4219 to 5646) +87% (+15% to+204%) 0.01
  Allergy/Immunology $4625 $4729 (3582 to 5876) +79% (+3% to+211%) 0.04
  Ophthalmology $4659 $4487 (2406 to 6568) +70% (-13% to +232%) 0.12
  Gastroenterology $4214 $3730 (3026 to 4434) +41% (-16% to +138%) 0.20
  Infectious Diseases $2713 $2658 (2034 to 3281) +1% (-44% to +80%) 0.98
  Pulmonology $2889 $2462 (2020 to 2904) −7% (−45% to +57%) 0.79
  Paediatric Specialty $1877 $1970 (1412 to 2528) −25% (−59% to +35%) 0.33
  Psychiatry $1722 $1852 (1229 to 2476) −30% (−62% to +29%) 0.25
  Radiology $2141 $1854 (1340 to 2368) −30% (−60% to +22%) 0.21
  Nephrology $1825 $1694 (1188 to 2199) −36% (−64% to +13%) 0.12
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Mean value of payments
Adjusted % difference (95% CI) P valueUnadjusted Adjusted (95% CI)
  Rehabilitation $1188 $1471 (1122 to 1820) −44% (-68% to -4%) 0.03
  Emergency Medicine $1400 $1341 (379 to 2303) −49% (−78% to +18%) 0.11
  Anaesthesiology $1088 $1106 (836 to 1375) −58% (-75% to -29%) <0.001
  Others† $1790 $1638 (1200 to 2075) −38% (−65% to +10%) 0.10
*Defined based on the U.S. News & World Report ranking (research ranking) in 2017.
†Others include surgical oncology, oral surgery, radio oncology, pathology, nuclear medicine and so on.
Table 2 Continued
that industry may be targeting certain types of physi-
cians—who are likely to be key thought leaders, content 
experts and clinical experts—who themselves may be 
prescribing a large amount of medications, or who may 
be influential in changing prescription practices of other 
physicians. Therefore, our findings should be informative 
for policymakers to design policies that can effectively 
minimise the influence of industry on medical practice. 
Further longitudinal studies are warranted to investi-
gate the causal effect of industry marketing on physician 
prescriptions and patient outcome.
Extensive research has shown that even small financial 
or in-kind gifts or compensation from industry may affect 
physicians’ decision-making.1 5 35 Yet, less is known about 
physician characteristics associated with receipt of larger 
industry payments. Prior studies included physician 
sex,14–16 years in practice,16 18 and clinical specialty10 15 16 
as physician-level covariates. Therefore, if there is a differ-
ence in sex distribution according to medical school 
research ranking, for example, then failing to adjust for 
medical school attended could lead to biased results. Our 
findings indicate that, even after adjustment for years in 
practice, medical school attended and specialty, male sex 
was still associated with larger payments from industry. 
This finding may be explained by the fact that female 
physicians may have different preferences for industry 
engagement36or that they may be less likely to negotiate 
for higher payments when they do engage with industry.14
Our findings indicate that physicians with more years 
in practice received higher payments from industry, 
compared with less experienced physicians, which is 
consistent with the recent findings using the 2014–2016 
Open Payments data.18 These findings may reflect the 
fact that industry is most interested in building relation-
ships with physicians who are experts in their field given 
that such expertise and experience can be obtained over 
many years of work in research and/or clinical practice.37 
Our finding that physicians who attended elite research 
medical schools on average, received higher industry 
payments than physicians who attended less prestigious 
research medical schools is also a new finding and may 
reflect these same tendencies.
We found that orthopaedic surgeons, neurosurgeons 
and endocrinologists received higher industry payments 
(both total and general payments) than physicians from 
other specialties, even after adjusting for other physician 
characteristics, including age and clinical experience. 
Meanwhile, we found that orthopaedic surgeons and 
neurosurgeons received fewer general payments from 
the industry when we restricted to general payments 
for drugs (ie, excluding general payments for devices). 
These results indicate that high industry payments to 
orthopaedic surgeons and neurosurgeons likely reflect 
payments from the medical device industry, a finding that 
has been previously demonstrated.38–40 Endocrinologists 
may receive higher payments from industry because they 
are centrally involved in treating several highly prevalent 
and expensive chronic diseases, including diabetes, hyper-
lipidaemia and obesity. Drug and medical device compa-
nies generate large amounts of revenue from treatments 
targeting these diseases. In 2017, for example, there 
were 25 (non-insulin) glucose-lowering agents among 11 
classes of therapies, creating a highly-competitive market 
for medications used by endocrinologists.41 This hypoth-
esis is supported by a recent study of industry payments 
to journal editors, which suggested that editors of endo-
crinology journals receive higher industry payments than 
editors of journals focused on other medical specialties.42
Our study has limitations. First, although the quality of 
Open Payments data has improved over time,13 it is still 
possible that the database has inaccuracies about the value 
of payments actually received by physicians. The Open 
Payments Data, however, are the most comprehensive 
and reliable data of industry payments to physicians avail-
able and the CMS encourages all physicians to review and 
dispute incorrect information prior to publication and 
nearly 30% of the total value of 2014 payments were actu-
ally reviewed.13 Second, our sample did not include physi-
cians who had no Medicare claims, and, therefore, these 
findings may not be generalisable to physicians not caring 
for Medicare beneficiaries. However, our findings were not 
qualitatively affected by inclusion of all physicians regard-
less of whether they were treating Medicare beneficiaries 
in sensitivity analyses. Third, although we included an 
extensive set of physician characteristics in our regression 
models, we could not rule out the possibility of residual 
confounding, due to unmeasured physician characteristics, 
not included in our analyses. Last, it is possible that phar-
maceutical and medical device companies underreport the 
value of payments to physicians.
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Table 3A Comparison of industry general payment value according to physician characteristics
Mean value of payments Adjusted % difference 
(95% CI) P valueUnadjusted Adjusted (95% CI)
Sex
  Female $804 $1142 (997 to 1287) Ref –
  Male $3053 $2627 (2488 to 2766) +130% (+104% to+159%) <0.001
Years in practice
  ≤10 $495 $744 (669 to 818) Ref –
  11–20 $2061 $2207 (2054 to 2359) +197% (+176% to +219%) <0.001
  21–30 $2856 $2895 (2531 to 3259) +289% (+222% to +371%) <0.001
  >30 $3344 $2540 (2309 to 2770) +241% (+206% to +281%) <0.001
Medical school attended*
  Top-20 school in USA $4024 $3014 (2720 to 3307) Ref –
  US schools ranked 21–50 $2570 $2250 (2047 to 2452) −25% (−34% to −15%) <0.001
  Other schools $2014 $2132 (1989 to 2275) −29% (−36% to −22%) <0.001
Specialty
  Primary care
  Internal Medicine $1188 $1268 (1193 to 1342) Ref –
  Family Medicine $506 $633 (478 to 788) −50% (−61% to −36%) <0.001
  Paediatrics $619 $817 (665 to 970) −36% (−47% to −22%) <0.001
  Hospitalist $183 $232 (178 to 287) −82% (−86% to −77%) <0.001
  Surgery
  Orthopaedic $14 502 $10 948 (8917 to 12979) +764% (+612% to +948%) <0.001
  Neurosurgery $13 807 $10 634 (4363 to 16905) +739% (+365% to +1414%) <0.001
  Thoracic/Vascular $5228 $3912 (3181 to 4643) +209% (+154% to +275%) <0.001
  Urology $2802 $2427 (2107 to 2748) +91% (+66% to +120%) <0.001
  Colorectal $3211 $2828 (2086 to 3570) +123% (+71% to +191%) <0.001
  General $2173 $2242 (1830 to 2654) +77% (+46% to +114%) <0.001
  Plastic $2171 $1958 (1547 to 2369) +54% (+25% to +91%) <0.001
  Otolaryngology $955 $875 (773 to 978) −31% (−39% to −22%) <0.001
  Obstetrics/Gynaecology $815 $926 (776 to 1075) −27% (−38% to −14%) <0.001
  Specialists
  Endocrinology $10 908 $10 560 (9324 to 11796) +733% (+633% to +847%) <0.001
  Rheumatology $6080 $6283 (5156 to 7411) +396% (+311% to +498%) <0.001
  Haematology/Oncology $6166 $5695 (5120 to 6270) +349% (+303% to +401%) <0.001
  Neurology $5871 $6296 (5604 to 6987) +397% (+339% to +461%) <0.001
  Dermatology $3435 $3902 (3463 to 4341) +208% (+172% to +249%) <0.001
  Cardiology $5146 $4021 (3751 to 4290) +217% (+192% to +245%) <0.001
  Allergy/Immunology $3331 $3280 (2729 to 3831) +159% (+117% to +209%) <0.001
  Ophthalmology $2629 $2263 (1849 to 2678) +79% (+48% to +116%) <0.001
  Gastroenterology $3487 $2978 (2658 to 3297) +135% (+109% to +164%) <0.001
  Infectious Diseases $2558 $2350 (1935 to 2766) +85% (+54% to +123%) <0.001
  Pulmonology $2689 $2211 (1887 to 2534) +74% (+49% to +104%) <0.001
  Paediatric Specialty $1749 $1650 (1324 to 1976) +30% (+6% to +60%) 0.01
  Psychiatry $1417 $1284 (1133 to 1436) +1% (−11% to +16%) 0.85
  Radiology $1229 $1118 (862 to 1375) −12% (−30% to +11%) 0.29
  Nephrology $1380 $1231 (957 to 1505) −3% (−23% to +22%) 0.80
Continued
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Mean value of payments Adjusted % difference 
(95% CI) P valueUnadjusted Adjusted (95% CI)
  Rehabilitation $1059 $1166 (975 to 1358) −8% (−22% to +9%) 0.34
  Emergency Medicine $668 $592 (512 to 672) −53% (−59% to −46%) <0.001
  Anaesthesiology $669 $671 (573 to 769) −47% (−55% to −38%) <0.001
  Others† $1190 $1122 (856 to 1388) −12% (−30% to +12%) 0.31
*Defined based on the U.S. News & World Report ranking (research ranking) in 2017.
†Others include surgical oncology, oral surgery, radio oncology, pathology, nuclear medicine and so on.
Table 3B OR of receiving research payments and comparison of the received payment value according to physician 
characteristics
No (%)
Median (IQR) annual payment value 
for physicians receiving payments Adjusted OR (95% CI) P value
Sex
  Female 1866 (1.1) $501 (127 to 2409) Ref –
  Male 7590 (2.1) $928 (167 to 4000) 1.73 (1.64 to 1.83) <0.001
Years in practice
  ≤10 423 (0.4) $376 (100 to 1186) Ref –
  11–20 2724 (1.7) $651 (200 to 2890) 3.51 (3.16 to 3.89) <0.001
  21–30 3017 (2.2) $868 (250 to 3980) 4.16 (3.74 to 4.62) <0.001
  >30 3292 (2.2) $1110 (283 to 4425) 3.46 (3.11 to 3.85) <0.001
Medical school attended*
  Top-20 school in USA 1793 (3.0) $1005 (299 to 4237) Ref –
  US schools ranked 21–50 1838 (1.9) $892 (217 to 3686) 0.73 (0.68 to 0.78) <0.001
  Other schools 5825 (1.5) $751 (219 to 3438) 0.61 (0.57 to 0.64) <0.001
Specialty
  Primary care
   Internal Medicine 1217 (1.2) $760 (197 to 3333) Ref –
   Family Medicine 439 (0.5) $646 (94 to 2823) 0.46 (0.40 to 0.52) <0.001
   Paediatrics 91 (1.4) $602 (271 to 1994) 1.29 (1.02 to 1.63) 0.35
   Hospitalist 17 (0.3) $1245 (400 to 2674) 0.24 (0.15 to 0.38) <0.001
  Surgery
   Orthopaedic 465 (2.2) $2240 (536 to 6650) 1.42 (1.25 to 1.62) 0.65
   Neurosurgery 209 (4.6) $1400 (333 to 4933) 3.01 (2.52 to 3.59) <0.001
   Thoracic/Vascular 100 (3.6) $350 (137 to 1096) 2.19 (1.77 to 2.72) <0.001
   Urology 192 (2.4) $717 (238 to 2703) 1.56 (1.32 to 1.86) <0.001
   Colorectal 33 (3.5) $466 (158 to 1900) 2.36 (1.58 to 3.52) <0.001
   General 467 (1.8) $437 (200 to 1330) 1.31 (1.15 to 1.49) <0.001
   Plastic 46 (1.8) $1197 (197 to 4483) 1.12 (0.83 to 1.52) 0.47
   Otolaryngology 150 (1.8) $446 (197 to 3771) 1.25 (1.03 to 1.52) 0.03
   Obstetrics/Gynaecology 505 (1.8) $331 (17 to 1839) 1.54 (1.36 to 1.74) <0.001
  Specialists
   Endocrinology 216 (4.9) $948 (147 to 5094) 4.02 (3.45 to 4.69) <0.001
   Rheumatology 244 (6.9) $688 (171 to 3615) 5.62 (4.77 to 6.62) <0.001
   Haematology/Oncology 1040 (11.1) $804 (183 to 2673) 8.90 (8.00 to 9.90) <0.001
   Neurology 564 (4.9) $653 (215 to 3608) 3.93 (3.47 to 4.44) <0.001
   Dermatology 360 (3.5) $2208 (363 to 10 648) 2.89 (2.52 to 3.31) <0.001
   Cardiology 567 (3.0) $754 (183 to 3159) 1.95 (1.73 to 2.20) <0.001
   Allergy/Immunology 155 (5.4) $3356 (550 to 21 467) 4.12 (3.39 to 5.00) <0.001
Table 3A Continued
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No (%)
Median (IQR) annual payment value 
for physicians receiving payments Adjusted OR (95% CI) P value
   Ophthalmology 476 (3.0) $1311 (418 to 5745) 2.09 (1.83 to 2.38) <0.001
   Gastroenterology 361 (3.5) $1667 (386 to 4330) 2.33 (2.01 to 2.69) <0.001
   Infectious Diseases 94 (2.0) $1102 (290 to 3770) 1.50 (1.21 to 1.85) <0.001
   Pulmonology 122 (2.2) $795 (280 to 3902) 1.51 (1.23 to 1.85) <0.001
   Paediatric Specialty 138 (3.9) $479 (180 to 1130) 3.00 (2.49 to 3.61) <0.001
   Psychiatry 240 (1.1) $1344 (459 to 7083) 0.87 (0.74 to 1.01) 0.07
   Radiology 241 (1.0) $2206 (525 to 7206) 0.68 (0.57 to 0.82) <0.001
   Nephrology 141 (2.0) $604 (263 to 3550) 1.46 (1.21 to 1.76) <0.001
   Rehabilitation 34 (0.5) $909 (188 to 3812) 0.37 (0.26 to 0.53) <0.001
   Emergency Medicine 122 (0.7) $567 (228 to 2000) 0.50 (0.41 to 0.61) <0.001
   Anaesthesiology 124 (0.3) $1343 (399 to 4042) 0.25 (0.21 to 0.31) <0.001
   Others† 286 (1.0) $728 (233 to 2493) 0.76 (0.66 to 0.87) <0.001
*Defined based on the U.S. News & World Report ranking (research ranking) in 2017.
†Others include surgical oncology, oral surgery, radio oncology, pathology, nuclear medicine and so on.
Table 3C OR of receiving ownership interests and comparison of the received payment value according to physician 
characteristics
Value invested No (%)
Median (IQR) annual 
payment value for 
physicians receiving 
payments Adjusted OR (95% CI) P value
Sex
  Female 305 (0.2) $33 (7 to 200) Ref Ref
  Male 1995 (0.5) $6000 (192 to 75 595) 2.20 (1.92 to 2.51) <0.001
Years in practice
  ≤10 48 (0.1) $3991 (6 to 22 954) Ref Ref
  11–20 525 (0.3) $6667 (193 to 25 000) 6.30 (4.67 to 8.49) <0.001
  21–30 806 (0.6) $4686 (280 to 35 217) 9.99 (7.48 to 13.35) <0.001
  >30 921 (0.6) $4686 (289 to 39 250) 9.68 (7.24 to 12.95) <0.001
Medical school attended*
  Top 20 school in USA 365 (0.6) $10 000 (755 to 33 339) Ref Ref
  US schools ranked 21–50 545 (0.6) $6202 (370 to 33 667) 1.00 (0.87 to 1.15) 0.96
  Other schools 1390 (0.4) $4500 (192 to 32 109) 0.75 (0.66 to 0.85) <0.001
Specialty
  Primary care 367 (0.2) $20 (7 to 57) Ref Ref
  Surgery 1275 (1.2) $8333 (425 to 38 155) 5.44 (4.58 to 6.46) <0.001
  Specialists 584 (0.3) $14 495 (1667 to 52 500) 1.18 (0.98 to 1.43) 0.09
  Others† 74 (0.3) $17 027 (3333 to 53 972) 1.18 (0.87 to 1.61) 0.29
Value of interest No (%) Median (IQR) annual 
payment value for 
physicians receiving 
payments
Adjusted OR (95% CI) P value
Sex
  Female 318 (0.2) $89 (11 to 11 591) Ref Ref
  Male 2154 (0.6) $13 890 (1944 to 52 247) 2.31 (2.03 to 2.63) <0.001
Years in practice
  ≤10 51 (0.1) $5649 (11 to 30 604) Ref Ref
Table 3B Continued
Continued
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Value invested No (%)
Median (IQR) annual 
payment value for 
physicians receiving 
payments Adjusted OR (95% CI) P value
  11–20 582 (0.4) $10 625 (755 to 30 882) 6.53 (4.90 to 8.71) <0.001
  21–30 901 (0.7) $11 067 (1100 to 46 933) 10.39 (7.86 to 13.74) <0.001
  >30 938 (0.6) $12 062 (1820 to 57 265) 9.13 (6.89 to 12.09) <0.001
Medical school attended*
  Top 20 school in USA 420 (0.7) $11 052 (1995 to 41805) Ref Ref
  US schools ranked 21–50 588 (0.6) $12 250 (1667 to 50 143) 0.94 (0.83 to 1.07) 0.35
  Other schools 1464 (0.4) $10 360 (660 to 42 659) 0.69 (0.61 to 0.78) <0.001
Specialty
  Primary care 377 (0.2) $69 (11 to 129) Ref Ref
  Surgery 1382 (1.3) $19 766 (3183 to 55 715) 5.69 (4.80 to 6.74) <0.001
  Specialists 637 (0.3) $12 178 (2500 to 67 629) 1.25 (1.04 to 1.50) 0.02
  Others† 76 (0.3) $17 707 (2504 to 70 084) 1.18 (0.87 to 1.59) 0.28
*Defined based on the U.S. News & World Report ranking (research ranking) in 2017.
†Others include surgical oncology, oral surgery, radio oncology, pathology, nuclear medicine and so on.
Table 3C Continued
COnCluSIOn
Using a contemporary national database of industry 
payments to physicians in 2015–2017, linked to a compre-
hensive database of practicing US physicians, we found 
that male physicians, more experienced physicians and 
physicians from medical schools with highly-ranked 
research programmes were more likely to receive higher 
payments from industry than other physicians. In addi-
tion, orthopaedic surgeons, neurosurgeons and endocri-
nologists received larger overall payments from industry 
than did other types of clinicians. These findings high-
light that promotional activities of the industry target 
clinician-scientists in specific specialties with sufficient 
clinical experience to influence prescribing practices.
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